BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 27113162)

  • 1. Impact of the introduction of the pneumococcal conjugate vaccine in the Brazilian routine childhood national immunization program.
    Moreira M; Cintra O; Harriague J; Hausdorff WP; Hoet B
    Vaccine; 2016 May; 34(25):2766-78. PubMed ID: 27113162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and impact of the 10-valent pneumococcal conjugate vaccine, PHiD-CV: review of clinical trials and post-marketing experience.
    Mrkvan T; Pelton SI; Ruiz-Guiñazú J; Palmu AA; Borys D
    Expert Rev Vaccines; 2018 Sep; 17(9):797-818. PubMed ID: 30185083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact after 10-year use of pneumococcal conjugate vaccine in the Brazilian national immunization program: an updated systematic literature review from 2015 to 2020.
    Guzman-Holst A; de Barros E; Rubio P; DeAntonio R; Cintra O; Abreu A
    Hum Vaccin Immunother; 2022 Dec; 18(1):1879578. PubMed ID: 33735585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of the 10-Valent Pneumococcal Nontypeable Haemophilus influenzae Protein D-Conjugated Vaccine (PHiD-CV) Against Carriage and Acute Otitis Media-A Double-Blind Randomized Clinical Trial in Finland.
    Vesikari T; Forsten A; Seppä I; Kaijalainen T; Puumalainen T; Soininen A; Traskine M; Lommel P; Schoonbroodt S; Hezareh M; Moreira M; Borys D; Schuerman L
    J Pediatric Infect Dis Soc; 2016 Sep; 5(3):237-248. PubMed ID: 27125273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modeling the impact of a new vaccine on pneumococcal and nontypable Haemophilus influenzae diseases: a new simulation model.
    De Wals P; Black S; Borrow R; Pearce D
    Clin Ther; 2009 Oct; 31(10):2152-69. PubMed ID: 19922887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nasopharyngeal carriage of otitis media pathogens in infants receiving 10-valent non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10), 13-valent pneumococcal conjugate vaccine (PCV13) or a mixed primary schedule of both vaccines: A randomised controlled trial.
    Beissbarth J; Wilson N; Arrowsmith B; Binks MJ; Oguoma VM; Lawrence K; Llewellyn A; Mulholland EK; Santosham M; Morris PS; Smith-Vaughan HC; Cheng AC; Leach AJ
    Vaccine; 2021 Apr; 39(16):2264-2273. PubMed ID: 33766422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct and Indirect Effectiveness of the 10-Valent Pneumococcal Conjugate Vaccine Against Carriage in a Cluster Randomized Trial.
    Palmu AA; Toropainen M; Kaijalainen T; Siira L; Lahdenkari M; Nieminen H; Syrjänen RK; Kilpi TM; Jokinen J
    Pediatr Infect Dis J; 2017 Dec; 36(12):1193-1200. PubMed ID: 28737627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of protein D-containing pneumococcal conjugate vaccines on non-typeable Haemophilus influenzae acute otitis media and carriage.
    Clarke C; Bakaletz LO; Ruiz-Guiñazú J; Borys D; Mrkvan T
    Expert Rev Vaccines; 2017 Jul; 16(7):1-14. PubMed ID: 28571504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 10-Valent pneumococcal non-typeable haemophilus influenzae protein D-conjugate vaccine: a review in infants and children.
    Plosker GL
    Paediatr Drugs; 2014 Oct; 16(5):425-44. PubMed ID: 25192686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine against acute otitis media and nasopharyngeal carriage in Panamanian children - A randomized controlled trial.
    Sáez-Llorens X; Rowley S; Wong D; Rodríguez M; Calvo A; Troitiño M; Salas A; Vega V; Castrejón MM; Lommel P; Pascal TG; Hausdorff WP; Borys D; Ruiz-Guiñazú J; Ortega-Barría E; Yarzabal JP; Schuerman L
    Hum Vaccin Immunother; 2017 Jun; 13(6):1-16. PubMed ID: 28368738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A cost-effectiveness analysis of PHiD-CV compared to PCV13 in a national immunization program setting in Tunisia.
    Lagoubi Y; Sfar MT; Gomez JA
    Hum Vaccin Immunother; 2022 Nov; 18(5):2079305. PubMed ID: 35703731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis of infant pneumococcal vaccination with PHiD-CV in Korea.
    Zhang XH; Leeuwenkamp O; Oh KB; Lee YE; Kim CM
    Hum Vaccin Immunother; 2018 Jan; 14(1):85-94. PubMed ID: 29115905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness analysis of routine pneumococcal vaccination in the UK: a comparison of the PHiD-CV vaccine and the PCV-13 vaccine using a Markov model.
    Delgleize E; Leeuwenkamp O; Theodorou E; Van de Velde N
    BMJ Open; 2016 Nov; 6(11):e010776. PubMed ID: 27903558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) on childhood pneumonia hospitalizations in Brazil two years after introduction.
    Scotta MC; Veras TN; Klein PC; Tronco V; Polack FP; Mattiello R; Pitrez PMC; Jones MH; Stein RT; Pinto LA
    Vaccine; 2014 Jul; 32(35):4495-4499. PubMed ID: 24958703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of the 10-valent pneumococcal non-typeable Haemophilus influenzae Protein D conjugate vaccine (PHiD-CV) on bacterial nasopharyngeal carriage.
    Prymula R; Hanovcova I; Splino M; Kriz P; Motlova J; Lebedova V; Lommel P; Kaliskova E; Pascal T; Borys D; Schuerman L
    Vaccine; 2011 Feb; 29(10):1959-67. PubMed ID: 21215830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety, reactogenicity and immunogenicity of 2-dose catch-up vaccination with 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Malian children in the second year of life: Results from an open study.
    Dicko A; Dicko Y; Barry A; Sidibe Y; Mahamar A; Santara G; Dolo A; Diallo A; Doumbo O; Shafi F; François N; Yarzabal JP; Strezova A; Borys D; Schuerman L
    Hum Vaccin Immunother; 2015; 11(9):2207-14. PubMed ID: 26020101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pneumococcal conjugated vaccine: PHiD-CV.
    Dinleyici EC; Yargic ZA
    Expert Rev Anti Infect Ther; 2009 Nov; 7(9):1063-74. PubMed ID: 19883326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced middle ear infection with non-typeable Haemophilus influenzae, but not Streptococcus pneumoniae, after transition to 10-valent pneumococcal non-typeable H. influenzae protein D conjugate vaccine.
    Leach AJ; Wigger C; Hare K; Hampton V; Beissbarth J; Andrews R; Chatfield M; Smith-Vaughan H; Morris PS
    BMC Pediatr; 2015 Oct; 15():162. PubMed ID: 26482232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pneumococcal conjugate vaccine for young children.
    Selman S; Hayes D; Perin LA; Hayes WS
    Manag Care; 2000 Sep; 9(9):49-52, 54, 56-7 passim. PubMed ID: 11116663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of 7-valent pneumococcal conjugate vaccine on invasive pneumococcal disease: a literature review.
    Myint TT; Madhava H; Balmer P; Christopoulou D; Attal S; Menegas D; Sprenger R; Bonnet E
    Adv Ther; 2013 Feb; 30(2):127-51. PubMed ID: 23397399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.